Prediction of CT Radiomics for Chemotherapy and Immunotherapy in Patient with Advanced Non-Small Cell Lung Cancer
10.3969/j.issn.1005-5185.2025.07.013
- VernacularTitle:CT影像组学预测晚期非小细胞肺癌化疗及免疫治疗效果
- Author:
Yuting LIU
1
;
Lei ZHAO
;
Aishi LIU
Author Information
1. 内蒙古医科大学附属医院影像诊断科,内蒙古 呼和浩特 010050
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Radiomics;
Chemotherapy,adjuvant;
Immunotherapy;
Pathology,clinical;
Forecasting;
Prognosis
- From:
Chinese Journal of Medical Imaging
2025;33(7):758-765
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To analyze the predictive value for the efficacy of chemotherapy and immunotherapy in patient with advanced non-small cell lung cancer(NSCLC).Materials and Methods A total of 120 patients with pathologically confirmed advanced NSCLC were retrospectively selected from September 2021 to October 2023 in the Affiliated Hospital of Inner Mongolia Medical University.All patients received programmed death receptor 1/programmed death receptor ligand 1 inhibitor monotherapy or chemotherapy combined with immunotherapy.The enhanced chest CT within three months of two courses(three to six weeks)for the evaluation of the clinical efficacy via the efficacy evaluation criteria of solid tumor version 1.1 was observed.According to the evaluation situation,all patients were divided into disease progression group(n=66)and disease without progression group(n=54).They were randomly divided into the training group and the verification group in a ratio of 7∶3.Among them,there were 46 patients with progression and 38 patients without progression in the training group.In the verification group,there were 20 patients with progression and 16 patients without progression.The regions of interest were segmented on the enhanced CT images of the chest within one month before the start of treatment,and the radiomics features were extracted and screened to establish the support vector machine learning model.The diagnostic efficacy of the model in predicting therapeutic effect was analyzed using the receiver operating characteristic curve,the calibration curve and decision curve were plotted to evaluate the prediction probability and clinical benefits of the model.Results Two clinical factors,namely the presence or absence of adrenal metastasis and the types of immune drugs,were included in the clinical model.Eleven of the most labeled radiomics characteristics were included in the radiomics model.The two were combined to construct a combined model.The area under the curve of the predictive efficiencies of the training group of the clinical model,the radiomics model and the clinical-radiomics combined model were 0.65,0.92 and 0.90,respectively;while the area under the curve of validation group were 0.64,0.83 and 0.85,respectively.Conclusion CT radiomics will have a high probability of non-invasively predicting the effects of chemotherapy and immunotherapy for advanced NSCLC.Especially the model combined with clinical characteristics has the best predictive efficacy.Radiomics can provide favorable guidance for the survival period and prognosis improvement of advanced NSCLC.
